"We know that the long-acting medications that we have today are tremendously effective in preventing long-term exacerbations in COPD, but compliance in this group is a very big challenge. Any advance that increases effectiveness and convenience of medication really has the potential to impact patient well-being."
Alistair Wheeler, vice president of clinical development and medical affairs at Sunovion Pharmaceuticals Inc., discussing the company's phase III program for SUN-101 in COPD

"Executives really understand that balancing innovation and risk comes with tradeoffs. They are still eager to bring products to market as quickly as possible, but that's going to take some give and take in terms of how they work with regulators and consumers."
Bobby Clark, senior manager, Pwc's Health Research Institute, during a webinar sponsored by Pwc to discuss its report The FDA and industry: A recipe for collaborating in the New Health Economy

"The growing GI market has attractive fundamentals, and Salix has a portfolio of terrific products that are out-pacing the market in terms of volume growth and a promising near-term pipeline of innovative products."
J. Michael Pearson, CEO, Valeant Pharmaceuticals International Inc., commenting on the company's acquisition of Salix Pharmaceuticals Ltd.